

ASX ANNOUNCEMENT

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

SYDNEY, Tuesday, 2 November 2021: Cellmid Limited (ASX: CDY) is pleased to advise that Phillip Christopher has been appointed to the Board of Cellmid as a non-executive director, effective on 5 November 2021. Phillip will stand for election at the upcoming general meeting of the shareholders and may remain on the Board of Cellmid while HGL Limited has an interest equal or greater than 5% in Cellmid.

Phillip is a highly accomplished investment professional with over 12 years' experience across private equity, mergers and acquisitions and capital markets. He has led a broad range of strategic investments throughout his career and provided board level support, corporate and commercial advice to investee companies.

Phillip is Investment Director of HGL Limited where he has been responsible for advising and guiding private investments including BLC Cosmetics prior to its acquisition by Cellmid. Phillip also spent 6 years at Alceon Group where he was a director in the private equity team which made significant investments in e-commerce and proprietary brand-based businesses. Prior to that he was a member of the investment banking division of Goldman Sachs. Phillip is a director of Pegasus Healthcare and was previously an alternate director of Marlin Brands. Educated at the University of Western Australia, Phillip graduated with a double degree in economics and commerce.

"We are delighted to welcome Phillip to the Board and looking forward to his strategic input in the significant growth prospect of the Company's health and beauty tech business", said Chairman of Board of Cellmid, Bruce Gordon.

"I am excited to join the Cellmid Board and looking forward to contributing to this new chapter of the Company's growth", said non-executive director, Phillip Christopher.

Approved for release by the Board of Directors.

Investor Enquiries:

The Capital Network Julia Maguire, Director T: +61 2 8999 3699

E: julia@thecapitalnetwork.com.au

Cellmid Limited (ASX: CDY)

Cellmid is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary brands of differentiated, clinically validated anti-aging solutions and the exclusive distribution of international cosmeceutical and wellness brands. For further information, please see www.evolisproducts.com.au and www.blccosmetics.com.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.